ArticleEuropean journal of neurology2025
Differences Between Females and Males in the Diagnostic Delay and Clinical Course of Thymectomised Myasthenia Gravis.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Women and Myasthenia Gravis.Annals of Indian Academy of Neurology · 2026Article
- Sex matters: mechanistic insights into sex-driven patterns of autoimmunity and implications for pharmacotherapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionMyasthenia gravis (MG) is an autoimmune disease presenting typically at an earlier age in females compared to males. However, whether sex affects the diagnostic delay and clinical course of MG has not been extensively explored in systematic cohorts.
methodsWe conducted a retrospective single-center cohort study on 251 thymectomized MG patients, including 124 males and 127 females. Mean follow-up was 10.7 (±9.1) years post-thymectomy. We analyzed factors associated with longer diagnostic delay and the type of first-onset symptoms (ocular vs. generalized). For 195 patients with nonthymomatous generalized MG (gMG) pre-thymectomy, we estimated the effect of diagnostic delay, symptoms at onset, and sex on reaching complete stable remission (CSR) or minimal need for medication (MNM) during postoperative follow-up. We also assessed their effect on the overall need for in-hospital treatments, immunosuppressant use, and pyridostigmine dose at the last follow-up visit.
resultsGeneralized symptoms at onset were more frequent for females than for males (n = 90, 70.9% vs. n = 65, 52.4%, respectively; p < 0.001). Diagnostic delay was significantly longer in females (6.0 months [0-117.5] vs. 3.2 months in males [0.1-84.0]; p = 0.012). First-onset symptoms and diagnostic delay did not affect the post-thymectomy prognosis of gMG. However, females achieved CSR (17.1% vs. 4.5%; p = 0.006) and MNM (30.8% vs. 16.9%; p = 0.029) more frequently and required fewer in-hospital treatments (40.6% vs. 55.2%; p = 0.010) and immunosuppressants (29.2% vs. 61.7%; p < 0.001) than males.
conclusionsWe report sex-related differences in symptoms at MG onset, length of diagnostic delay, and prognosis, the origins of which should be further studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.